Led · Series A · May 2026

Dandelion Health develops a multimodal clinical AI platform intended to inform drug development and redesign clinical trial design using high-fidelity longitudinal clinical data. The company positions its platform to better characterize pre-disease windows and patient trajectories so trials are built against current clinical realities rather than outdated disease definitions. Leadership mentioned in the announcement includes Elliott Green and Niyum Gandhi, and the company has attracted investors with healthcare and scientific expertise. Financially, the company completed a $14 million Series A led by new investors Healthier Capital and Colle Capital alongside returning investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures. Dandelion says the new capital will be applied to continue developing its clinical-AI capabilities and expanding its platform's use in life sciences and AI development. The article does not disclose revenue, user, or other operating metrics.

Led · Series A · Apr 2026

Photon builds a full-stack prescription infrastructure combining digital prescribing and routing infrastructure, a pharmacy network, and a consumer-facing marketplace that surfaces real-time price and stock information. The platform includes capabilities such as prior authorization and clinical decision support and relies on AI to process complex pharmacy, benefits, and formulary data in real time. Photon began in direct-to-consumer digital health and has expanded into health systems, integrating with in-house pharmacies and provider workflows. Since its founding in 2021, the company says it has helped millions of patients make more informed pharmacy decisions. Photon plans to deepen marketplace integrations and expand health system partnerships to increase in-house pharmacy utilization and reduce administrative burden across the medication journey.

Participated · Series B · Mar 2026

Qualified Health provides a secure enterprise AI platform and strategic services to help health systems deploy AI with embedded safety, governance, and monitoring. Its platform combines workflow automation, agent development, clinical safeguards, real-time monitoring, and end-to-end traceability. Early deployments with partners including Mercy, Emory Healthcare, University of Rochester Medicine, Jefferson Health, and the University of Texas System have produced measurable revenue uplift and cost savings, including more than $15 million in run-rate impact at UTMB within six months. The platform currently supports more than 500,000 users across health systems representing approximately 7% of U.S. hospital revenue. The company is led by former health system executives, frontline physicians, clinical transformation experts, and Silicon Valley engineers. Qualified Health plans to deepen partnerships and scale its platform responsibly while expanding governance, monitoring, and infrastructure to support mission-critical AI deployments.

Led · Series A · Jan 2026

Founded in 2024, Zarminali Pediatrics is building a national multispecialty pediatric health system that unifies primary, specialty, and urgent care under one technology-driven platform. The company currently runs 28 outpatient clinics across eight states and positions itself as a single destination for families seeking comprehensive pediatric services. Its proprietary technology backbone supports coordinated care and alleviates administrative burdens for clinicians, while enhancing access for patients through features such as planned 24/7 telehealth. In 2026, Zarminali intends to open 15 additional de novo clinics in new markets including Chicago, Milwaukee, and Dallas and to broaden its service mix to speech, occupational, and behavioral health therapies. The model emphasizes family-centered design, empowered clinicians, and seamless care coordination. Following its $110 million Series A, the company has raised $150 million in total funding to fuel rapid clinic expansion and technology development.

Participated · Series B · Nov 2025

Amae Health is a San-Francisco–based Public Benefit Corporation focused on treating severe mental illness (SMI) through a combination of compassionate, team-based outpatient care and an AI-powered precision-medicine platform built on Palantir Foundry. Its clinics, first launched in Los Angeles in 2022, partner with leading health systems such as NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care to deliver coordinated treatment from psychiatrists, therapists, primary-care providers, dietitians, and social-services specialists. The company reports strong clinical outcomes, including reducing 30-day hospital readmissions to under 4% versus a 23% national average, improving measurement-based scores by up to 76% in mania, and maintaining a Net Promoter Score of 90. Key platform features—Patient-at-a-Glance, Point of Care Assistant, and Symptomology Phenotyping—help clinicians tailor interventions and monitor progress. Amae plans to use new capital to expand clinics nationwide, advance its AI tools, and support research into schizophrenia, bipolar disorder, and treatment-resistant depression through the newly formed Amae Institute. To date, the company has raised more than $50 million in funding, underscoring investor confidence in its integrated model and long-term goal of achieving five-year remission cures.